Y. Chou

发表

Induction of T cell anergy by high concentrations of immunodominant native peptide is accompanied by IL-10 production and a block in JNK activity.

A. Vandenbark, H. Offner, I. Robey, 1998, Cellular immunology.

Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis.

G. Nedwin, A. Vandenbark, H. Offner, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Immunity to TCR peptides in multiple sclerosis. II. T cell recognition of V beta 5.2 and V beta 6.1 CDR2 peptides.

D. Bourdette, A. Weinberg, A. Vandenbark, 1994, Journal of immunology.

Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar V alpha and V beta chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different

N. Shen, A. Vandenbark, H. Offner, 1989, The Journal of experimental medicine.

Immunity to TCR peptides in multiple sclerosis. I. Successful immunization of patients with synthetic V beta 5.2 and V beta 6.1 CDR2 peptides.

D. Bourdette, A. Vandenbark, H. Offner, 1994, Journal of immunology.

Diminished frequency of interleukin‐10‐secreting, T‐cell receptor peptide‐reactive T cells in multiple sclerosis patients might allow expansion of activated memory T cells bearing the cognate BV gene

D. Bourdette, D. Barnes, A. Vandenbark, 2001, Journal of neuroscience research.

MHC‐restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR Vβ CDR2 peptides: Comparison with myelin basic protein‐specific T cells

D. Bourdette, H. Offner, I. Robey, 1996, Journal of neuroscience research.

Suppressor cell regulation of encephalitogenic T cell lines: generation of suppressor macrophages with cyclosporin A and myelin basic protein.

D. Bourdette, A. Vandenbark, H. Offner, 1990, Cellular immunology.

Human T lymphocyte response to myelin basic protein: Selection of T lymphocyte lines from mbp‐responsive donors

D. Bourdette, A. Vandenbark, H. Offner, 1989, Journal of neuroscience research.

T cell receptor peptide therapy for autoimmune disease.

D. Bourdette, A. Vandenbark, H. Offner, 1992, Journal of autoimmunity.

Differential susceptibility of human T(h)1 versus T(h) 2 cells to induction of anergy and apoptosis by ECDI/antigen-coupled antigen-presenting cells.

D. Bourdette, D. Barnes, A. Vandenbark, 2000, International immunology.

Specificity of human T cell clones reactive to immunodominant epitopes of myelin basic protein

D. Bourdette, A. Vandenbark, H. Offner, 1991, Journal of neuroscience research.

Human CD8+ T cell clone regulates autologous CD4+ myelin basic protein specific T cells.

A. Vandenbark, H. Offner, P. Henderikx, 1992, Autoimmunity.

Effects of vaccination with T cell receptor peptides: Epitope switching to a possible disease‐protective determinant of myelin basic protein that is cross‐reactive with a TCR BV peptide

D. Bourdette, A. Vandenbark, H. Offner, 1998, Immunology and cell biology.

Response of human T lymphocyte lines to myelin basic protein: Association of dominant epitopes with HLA class II restriction molecules

D. Bourdette, A. Vandenbark, H. Offner, 1989, Journal of neuroscience research.

Selectin of encephalitogenic rat T‐Lymphocyte clones recognizing an immunodominant epitope on myelin basic protein

A. Vandenbark, H. Offner, Y. Chou, 1989, Journal of neuroscience research.

Encephalitogenic T cell clones with variant receptor specificity.

H. Offner, Y. Chou, G. Hashim, 1988, Journal of immunology.

Episodic changes in T‐cell frequencies to myelin basic protein in patients with multiple sclerosis

D. Bourdette, A. Vandenbark, H. Offner, 1993, Neurology.

T cell receptor Vβ gene usage in the recognition of myelin basic protein by cerebrospinal fluid‐ and blood‐derived T cells from patients with multiple sclerosis

D. Bourdette, A. Vandenbark, H. Offner, 1994 .

Immunity to T cell receptor peptides in multiple sclerosis. III. Preferential immunogenicity of complementarity-determining region 2 peptides from disease-associated T cell receptor BV genes.

D. Bourdette, G. Nepom, A. Vandenbark, 1998, Journal of immunology.

TCR peptide therapy regulates basic protein specific T cell frequency in patients with multiple sclerosis

D. Bourdette, A. Vandenbark, H. Offner, 1991, Journal of Neuroimmunology.

Immunity to TCR peptides in multiple sclerosis: II. T cell recognition of Vb5.2 and Vb6.1 CDR2 peptides

R. Whitham, Y. Chou, G. Hashim, 1994, Journal of Immunology.